Product category:
Cell/tissue handling and counting
News Release from: Abcellute
Edited by the Laboratorytalk Editorial
Team on 23 November 2006
Exclusive agreement with GeneFrontier
Abcellute and GeneFrontier have signed an exclusive agreement for the manufacture, marketing and distribution of Abcellute's preserved hepatocyte products into Japan
GeneFrontier is also permitted to establish sub-licences with pharmaceutical and similar companies actively involved in the pre-clinical evaluation of new candidate drugs, for their internal use of the Abcellute cell preservation technology "The contract signed today is a significant milestone in Abcellute's strategy to extend the adoption of its cell preservation technology platform on a global basis
This article was originally published on Laboratorytalk on 1 Mar 2007 at 8.00am (UK)
Related stories
Cell preservation to reduce experiment animal use
Breakthrough cell preservation method to reduce animal use in experiments has been presented to UK members of parliament (MPs) at NC3Rs event.
Blood vessel viability can be stretched
In what is described as a major breakthrough Abcellute's non-cryogenic cell preservation technology has been successfully trialled by Biopta, a CRO specialising in human tissue in vitro pharmacology
"We are delighted that the pharmaceutical industry in Japan, through our relationship with GeneFrontier, will now have immediate and direct access to the technology", commented Alex Watson, Abcellute's chief executive officer.
"The agreement with Abcellute marks a huge first step to introduce Abcellute's proprietary cell preservation technology applied to hepatocytes into the Japanese pharmaceutical market.
"This technology permits pharmaceutical companies to perform pre-clinical toxicology evaluations of new candidate drugs using hepatocytes which are preserved at non-freezing temperatures for the working week and which exhibit cell viability and metabolic activity in keeping with freshly isolated hepatocytes", commented Makoto Ogasawara, president and CEO of GeneFrontier.
"We are convinced that today's announcement will increase the awareness of Abcellute's innovative cell preservation technology, which has the potential to add efficacy to the pre-clinical evaluation process in Japan, resulting in shortening the lengthy drug-discovery processes".
Abcellute was founded in 2001 and is a spinout from the School of Biosciences, Cardiff University.
The company's core platform technology permits the preservation and storage of fresh primary hepatocytes for up to five days at non-freezing temperatures without loss of biological function or principle biomarkers.
Preservation is achieved through the immersion of the cells in a unique matrix which coats and protects them.
The retention of total cell integrity and full profile of drug metabolising enzymes (including Phase II) provides the first effective solution to the needs of the pharmaceutical industry, in the pre-clinical evaluation (Admet) of new drug candidates.
Prior to use, the cells are re-activated and subsequently behave as normal fresh cells, retaining their 'intact whole organ' characteristics.
• Abcellute: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
